ASCO, Author Interviews, Cancer Research, Radiation Therapy / 13.06.2018 Interview with: Jonathan Strosberg MD Moffitt Cancer Center, Tampa, FL What is the background for this study? Response: Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life. We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related quality of life in patients with advanced midgut neuroendocrine tumors in the NETTER-1 study. (more…)